Printer Friendly

MEDICAL GRAPHICS RECEIVES PATENT PROTECTION ON COMPONENT OF LUNG DIAGNOSTIC LABS;

 MEDICAL GRAPHICS RECEIVES PATENT PROTECTION
 ON COMPONENT OF LUNG DIAGNOSTIC LABS;
 Device Is Key to Infection Control
 St. Paul, Minn., March 10 /PRNewswire/ -- Medical Graphics Corporation (NASDAQ: MGCC) today announced that it received patent protection on a component of its lung diagnostic systems. The U.S. Patent and Trademark Office recently notified the company that it has allowed a patent for Medical Graphics' patient breathing circuit.
 The patient breathing circuit is a multi-functional valve that controls the flow of the patient's inspired and expired air during lung function testing. Because it is disposable, it removes a source of cross-contamination and provides infection control. Concern for infection control grows with prevalence of infectious diseases
 "Tuberculosis, hepatitis, and other infectious diseases are on the rise. For physicians and their patients, concerns for cross- contamination are only too real. As you can imagine, infection control is absolutely critical," said Catherine A. Anderson, chairman, president and chief executive officer of Medical Graphics. "Medical Graphics is the only company in the industry with complete lung diagnostic systems that provide true infection control for safe and thorough testing."
 The company's new line of pulmonary diagnostic systems use disposable and easily-removable patient-contact components. The MedGraphics PF/Dx, a pulmonary function diagnostic system which recently received FDA market clearance, and the MedGraphics 1085/D, a body plethysmograph, feature the company's patented disposable pneumotach, a small device that accurately measures air flow; and the patient breathing circuit. Both components quickly snap on and off the systems, eliminating concerns for cross-contamination between patients.
 Physicians, respiratory therapists and other clinicians use the PF/Dx and 1085/D to non-invasively diagnose the cause of shortness of breath and obstructive lung diseases such as asthma, emphysema, and bronchitis. The systems are used for monitoring these lung conditions, as well therapy for cancer and AIDS-related pneumonia. The PF/Dx and 1085/D provide objective data to document the need for medication or surgery, and to measure the outcome.
 Medical Graphics Corporation develops computerized non-invasive cardiorespiratory diagnostic and monitoring systems for the early diagnosis, treatment and prevention of heart and lung disease. Since its founding in 1977, the company has pioneered every major technological breakthrough in cardiorespiratory diagnostics. With headquarters in St. Paul, Minnesota and Dusseldorf, Germany, Medical Graphics does business in more than 30 countries around the world.
 -0- 3/10/92
 /CONTACT: Marie Overfors of Medical Graphics, 612-484-4874/
 (MGCC) CO: Medical Graphics Corporation ST: Minnesota IN: MTC SU:


KH -- MN009 -- 6975 03/10/92 14:46 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 10, 1992
Words:414
Previous Article:PETRO PLUS INC. ANNOUNCES SIGNING OF CONTRACT WITH HUSKY OIL MARKETING CO.
Next Article:'WAITING FOR THE WIND' WINS GOLD ANGEL
Topics:


Related Articles
MEDICAL GRAPHICS CLEARED TO MARKET BREAKTHROUGH LUNG DIAGNOSTIC SYSTEM:
QRS Diagnostic Appoints Ed Schuck to Its Board of Directors; Respected Medical Device Industry Veteran Brings Valuable Experience to QRS.
QRS Diagnostic and Sunlight Medical Now Offer their Compatible Medical Device Technologies to Physicians in the United States; Sunlight's...
Nanogen issued patent for device that combines optical waveguides and molecular diagnostics.
Protein Design Labs Elects Samuel Broder, M.D. to Board of Directors.
Patenting life forms.
First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval.
Rosetta Genomics Completes Acquisition of Parkway Clinical Laboratories Inc.
Rosetta Genomics Reports Second Quarter 2008 Financial Results.
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters